CION Ameerpet
For a woman in her teens or twenties with an ovarian mass, CA-125 is frequently the wrong test. The tumours that occur at that age produce different substances entirely — and sending the wrong panel is a genuinely common and avoidable gap.
Ovarian tumours are not the same at every age, and this has a direct practical consequence that is frequently missed. In women over about 40, the great majority are epithelial tumours — arising from the surface cells — and CA-125 is the relevant marker for those.
In adolescents and young women the picture is different. Here germ cell tumours — arising from the egg-producing cells themselves — make up a much larger proportion. And germ cell tumours do not reliably produce CA-125. They produce entirely different substances: alpha-fetoprotein, beta-hCG and lactate dehydrogenase, depending on the specific type.
So sending a CA-125 alone for a 19-year-old with an ovarian mass is not a thorough work-up — it is the wrong panel. A normal result reassures nobody who understands what was actually measured, and the markers that would have been informative were never checked. This gap is common, avoidable, and worth asking about directly.
Arising from surface cells. CA-125 is the relevant marker for these.
Arising from egg-producing cells, and they do not reliably produce CA-125 at all.
A normal CA-125 in a young woman says little if the markers that mattered were never sent.
Ovarian germ cell tumours are, in general, among the more treatable cancers there are — a genuinely important point that gets lost when a young woman is told she has ovarian cancer and reads statistics drawn from a completely different disease. They are typically highly responsive to chemotherapy, frequently diagnosed at an early stage, and because they usually affect one ovary, fertility-sparing surgery is often possible — removing the affected ovary while preserving the other and the uterus. The outlook is substantially better than for the epithelial ovarian cancer that dominates the statistics people find online. Source: NCCN Ovarian Cancer including Fallopian Tube and Primary Peritoneal Cancer guidelines.
Different germ cell tumour types produce different substances, so the pattern across the panel is itself informative.
| Marker | Typically raised in | Notes |
|---|---|---|
| AFP (alpha-fetoprotein) | Yolk sac tumour; some mixed germ cell tumours and immature teratomas. | A markedly raised AFP in a young woman with an ovarian mass strongly suggests a yolk sac component. |
| Beta-hCG | Choriocarcinoma; some dysgerminomas and mixed tumours. | Also raised in pregnancy — a pregnancy test is essential before interpreting it. |
| LDH | Dysgerminoma most characteristically. | Non-specific and raised in many conditions, but useful within the panel and for monitoring. |
| CA-125 | Epithelial ovarian tumours. | Often normal in germ cell tumours. Not the relevant marker in this age group. |
| Inhibin B | Granulosa cell tumours (sex cord-stromal, not germ cell). | A different tumour family again. See inhibin B. |
*The pattern across the panel helps indicate the tumour type before surgery, which informs how the operation is planned — particularly whether fertility-sparing surgery is appropriate.
They do three separate jobs: pointing to a diagnosis, guiding surgery, and tracking treatment.
In a young woman with a solid or rapidly growing ovarian mass, a markedly raised AFP or beta-hCG points strongly towards a germ cell tumour before any tissue has been examined. That changes the surgical plan considerably — it signals that fertility-sparing surgery should be actively considered rather than a more extensive operation performed by default.
It also flags the need for a specialist team. Germ cell tumours are uncommon, and outcomes are better where they are managed by clinicians who see them regularly. The marker result is often what triggers that referral.
Beta-hCG is the pregnancy hormone, so a pregnancy test is essential before interpreting a raised result. This is not a formality — a young woman with a pelvic mass and a raised beta-hCG could have a pregnancy, an ectopic pregnancy, or a germ cell tumour, and those need completely different responses.
An ectopic pregnancy in particular is an emergency that presents with pelvic pain and a raised beta-hCG, and it must be excluded urgently rather than assumed against. This is standard practice and it is why the test is done first.
Because germ cell tumours usually affect one ovary and occur in young women, preserving fertility is a central consideration rather than an afterthought. Surgery typically removes the affected ovary and tube while leaving the other ovary and the uterus intact, allowing future pregnancy.
This should be discussed before the operation, not afterwards. If a young woman is having surgery for an ovarian mass and nobody has raised fertility, that is a gap worth pressing on. See fertility and ovarian cancer.
Where markers were raised at diagnosis, they become genuinely useful for tracking treatment. Germ cell tumours are typically highly chemo-sensitive, and a falling marker is often the earliest available sign that treatment is working — frequently visible before any scan is repeated.
The rate of fall carries information too. Markers that fall promptly and predictably indicate good response; a plateau or a rise prompts reassessment of the regimen. This is analogous to how CA-125 is used in epithelial disease. See marker monitoring.
After treatment finishes, serial marker measurement forms part of follow-up. Because these markers were informative at diagnosis, a rise during surveillance is meaningful in a way it would not be in a woman whose markers were never raised.
As always, a single rise is repeated rather than acted on immediately, and symptoms and imaging sit alongside the numbers. But in germ cell tumours the markers tend to be more reliable indicators than CA-125 is in epithelial disease.
Not every germ cell tumour secretes markers. Dysgerminomas may raise only LDH, which is non-specific, and immature teratomas can produce normal markers entirely. A pure dysgerminoma or immature teratoma can present with an entirely normal panel.
So normal markers do not exclude a germ cell tumour, and a solid or rapidly growing ovarian mass in a young woman warrants proper assessment regardless. The imaging and the clinical picture lead; the markers add information when raised.
These are the gaps that most often occur, and each has a quick specific answer.
AFP, beta-hCG and LDH — not CA-125 alone. This is the commonest omission in this age group.
Essential before interpreting beta-hCG, and ectopic pregnancy must be excluded urgently in any case.
It should be raised before surgery, not after. Fertility-sparing surgery is frequently possible here.
Germ cell tumours are uncommon and outcomes are better with a team that sees them regularly.
Multidisciplinary review matters particularly for uncommon tumours in young patients.
Both raise the suspicion of a germ cell tumour in a young woman and warrant prompt assessment.
Sudden severe pain with a known ovarian mass in a young woman needs same-day assessment — germ cell tumours can present with torsion or rupture. See ovarian torsion.
A CA-125 alone in a young woman with an ovarian mass is an incomplete work-up. It is a quick question with a specific answer and it is worth asking.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Chemotherapy is delivered in-house at CION; fertility-sparing surgery is coordinated with specialist partner centres.
A young woman told she has an ovarian mass will search ovarian cancer and find statistics that describe a different disease entirely — epithelial cancer in post-menopausal women, frequently diagnosed late. That is not her situation, and the gap between what she reads and what she has is a source of considerable and unnecessary fear.
Your first consultation at CION is free and runs to about 45 minutes. If you are attending for a daughter, sister or yourself, bring the scan report and ask specifically which markers were sent — a CA-125 alone in this age group is an incomplete work-up, and it is a quick thing to correct. Fertility should be part of the conversation before any operation rather than after it.
Chemotherapy is delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, which matters here because germ cell tumours are typically highly chemo-sensitive and treatment can continue near where you live. Surgery, including fertility-sparing procedures, is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. Every case that raises a question goes to a tumour board.
Germ cell tumours behave and respond quite differently from the epithelial cancer that dominates search results.
AFP, beta-hCG and LDH. A CA-125 alone in a young woman is an incomplete work-up.
Fertility-sparing surgery is frequently possible. It should be discussed before the operation, not after.
Delivered across 35+ centres, which matters given how chemo-sensitive these tumours typically are.
This deserves saying directly, because almost nothing a young woman finds online will say it. Ovarian germ cell tumours are among the more treatable cancers. They are typically highly responsive to chemotherapy, they are frequently found at an early stage because they grow quickly and cause symptoms, and they usually involve one ovary.
That combination — chemo-sensitive, often early, usually unilateral — means the outlook is substantially better than for the epithelial ovarian cancer that dominates the statistics. It also means fertility can frequently be preserved, with many women going on to conceive naturally after treatment.
None of this makes a diagnosis easy, and none of it should be used to minimise what a young woman and her family are going through. But the numbers she will find by searching are not her numbers, and somebody should tell her that early rather than leaving her to discover it weeks later.
These tumours generally respond well to chemotherapy, which is central to why the outlook is good.
They grow quickly and cause symptoms, so they tend to present before extensive spread.
Which is what makes fertility-sparing surgery possible in a large proportion of cases.
Statistics online describe epithelial cancer in older women. That is a different disease.
Because the tumours that occur at that age are usually different. In women over about 40 the great majority of ovarian tumours are epithelial, arising from the surface cells, and CA-125 is the relevant marker. In adolescents and young women, germ cell tumours — arising from the egg-producing cells — make up a much larger proportion, and these do not reliably produce CA-125 at all. They produce alpha-fetoprotein, beta-hCG and lactate dehydrogenase instead. So a CA-125 alone in a young woman with an ovarian mass is the wrong panel, and a normal result reassures nobody who understands what was measured.
Different germ cell tumour types produce different substances, so the pattern across the panel is informative. A markedly raised AFP suggests a yolk sac tumour or a mixed tumour containing yolk sac elements. Beta-hCG is raised in choriocarcinoma and in some dysgerminomas and mixed tumours — though it is also the pregnancy hormone, so a pregnancy test is essential before interpreting it. LDH is most characteristically raised in dysgerminoma, though it is non-specific and rises in many conditions. Together they help indicate the likely tumour type before any tissue is examined.
Yes. Not every germ cell tumour secretes markers. Dysgerminomas may raise only LDH, which is non-specific, and immature teratomas can produce an entirely normal panel. So normal markers do not exclude a germ cell tumour, and a solid or rapidly growing ovarian mass in a young woman warrants proper assessment regardless of what the blood tests show. The imaging and the clinical picture lead; the markers add useful information when they are raised, and their absence does not close the question.
Frequently, yes, and it is a central consideration rather than an afterthought. Ovarian germ cell tumours usually affect one ovary and occur in young women, so surgery typically removes the affected ovary and tube while leaving the other ovary and the uterus intact, allowing future pregnancy. Many women go on to conceive naturally after treatment. The important point is that this should be discussed before the operation rather than afterwards — if a young woman is having surgery for an ovarian mass and nobody has raised fertility, that is a gap worth pressing on.
Generally very — and this deserves stating plainly, because almost nothing a young woman finds by searching will say it. Germ cell tumours are typically highly responsive to chemotherapy, are frequently found at an early stage because they grow quickly and cause symptoms, and usually involve only one ovary. That combination means the outlook is substantially better than for the epithelial ovarian cancer that dominates online statistics. The numbers found by searching "ovarian cancer survival" describe a different disease in a different age group, and are not applicable.
Because beta-hCG is the pregnancy hormone, so a raised result cannot be interpreted without knowing whether you are pregnant. This is not a formality. A young woman with a pelvic mass and a raised beta-hCG could have a normal pregnancy, an ectopic pregnancy, or a germ cell tumour — and those require completely different responses. Ectopic pregnancy in particular is an emergency that presents with pelvic pain and a raised beta-hCG, and it must be excluded urgently rather than assumed against. Doing the pregnancy test first is standard practice for exactly this reason.
The first consultation is free and runs to about 45 minutes — bring the scan report and ask specifically which markers were sent, since a CA-125 alone in this age group is an incomplete work-up. Chemotherapy is delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, which matters given how chemo-sensitive these tumours typically are. Surgery, including fertility-sparing procedures, is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. Every case that raises a question is reviewed at a tumour board.